Browsing Tag
AREXVY
3 posts
Clover Biopharmaceuticals receives FDA clearance for RSV vaccine trial, expands respiratory disease research
Clover Biopharmaceuticals advances RSV vaccine research with FDA-approved SCB-1019 trials, targeting revaccination gaps and combination immunization strategies.
Canada approves GSK’s Arexvy vaccine for RSV protection in adults 50-59 at elevated risk
In a crucial development for public health, Health Canada has extended its approval for GlaxoSmithKline’s Arexvy vaccine to…
FDA extends approval for GSK’s RSV vaccine, AREXVY, to adults aged 50-59 at increased risk
The U.S. Food and Drug Administration (FDA) has officially broadened the age indication for GSK plc’s (LSE/NYSE: GSK)…